Doing Well By Doing Good: FDA's Orphan Product Head Makes His Case to Pharma
This article was originally published in RPM Report
Executive Summary
Tim Coté has been a tireless advocate for greater involvement by Big Pharma in orphan drug research since taking over as head of FDA's Orphan Products Office two years ago. We talked to him about the response he's heard so far.